CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted EBITDA Margin of -987.22% for Q3 2026, up 13368.91 percentage points from -14356.13% a year earlier and up 122.58 percentage points from the prior quarter.
CRISPR Therapeutics AG (CRSP) EBITDA Margin (2016 - 2026) Analysis & Trends
For the trailing twelve months through Sep 30, 2026, EBITDA Margin at CRISPR Therapeutics AG was -2038.34%, down 588.74 percentage points year-over-year; for FY2025, it came in at -18378.69%, down 17179.92 percentage points from FY2024.
- Annual EBITDA Margin shows a five-year change of +29639.53 percentage points (FY2020 to FY2025).
- In prior years, CRISPR Therapeutics AG's EBITDA Margin was -1198.76% in FY2024 (-1144.16 pp), -54.61% in FY2023 (+54118.10 pp), -54172.70% in FY2022 (-54215.49 pp) and 42.79% in FY2021 (+48061.01 pp).
- The Q3 2026 figure stands as the highest quarterly EBITDA Margin since Q4 2024.
- On a year-over-year basis, EBITDA Margin has increased in each of the last three quarters, with an average year-over-year change of +5591.73 percentage points over the last eight quarters.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was Q4 2023, with a gain of 2094953.68 percentage points; the weakest was Q4 2022, with a drop of 2093835.68 percentage points.
- According to Business Quant data, EBITDA Margin for the three prior quarters was -1109.80% (Q2 2026), -8637.11% (Q1 2026) and -17257.29% (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 54.65% |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 40.75% |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | - |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 42.49% |
| 10 | CRISPR Therapeutics AG | 4.65 Bn | -4.41 Bn | - | -987.22% |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -987.22% |
| Jun 30, 2026 | -1,109.80% |
| Mar 31, 2026 | -8,637.11% |
| Dec 31, 2025 | -17,257.29% |
| Sep 30, 2025 | -14,356.13% |
| Jun 30, 2025 | -25,187.78% |
| Mar 31, 2025 | -16,611.33% |
| Dec 31, 2024 | -167.40% |
| Sep 30, 2024 | -17,506.81% |
| Jun 30, 2024 | -28,320.12% |
| Mar 31, 2024 | -26,935.32% |
| Dec 31, 2023 | 37.02% |
| Jun 30, 2023 | -128.95% |
| Mar 31, 2023 | -59.44% |
| Dec 31, 2022 | -2,094,916.67% |
| Sep 30, 2022 | -188,691.49% |
| Jun 30, 2022 | -111,386.71% |
| Mar 31, 2022 | -18,077.98% |
| Dec 31, 2021 | -1,080.99% |
| Sep 30, 2021 | -14,990.90% |
CRISPR Therapeutics AG EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CRSP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "CRSP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CRSP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();